133 related articles for article (PubMed ID: 33868476)
1. Recombinant protein TRAIL-Mu3 enhances the antitumor effects in pancreatic cancer cells by strengthening the apoptotic signaling pathway.
Huang M; Yi C; Huang XZ; Yan J; Wei LJ; Tang WJ; Chen SC; Huang Y
Oncol Lett; 2021 Jun; 21(6):438. PubMed ID: 33868476
[TBL] [Abstract][Full Text] [Related]
2. A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer.
Huang M; Zhu H; Yi C; Yan J; Wei L; Yang X; Chen S; Huang Y
Cancer Chemother Pharmacol; 2018 Nov; 82(5):829-838. PubMed ID: 30167846
[TBL] [Abstract][Full Text] [Related]
3. [Antitumor Activity of TRAIL-Mu3 Protein
Yang T; Zhu AJ; Wang JS; Jin Z
Sichuan Da Xue Xue Bao Yi Xue Ban; 2020 May; 51(3):304-311. PubMed ID: 32543134
[TBL] [Abstract][Full Text] [Related]
4. TRAIL induces apoptosis but not necroptosis in colorectal and pancreatic cancer cells preferentially via the TRAIL-R2/DR5 receptor.
Nahacka Z; Svadlenka J; Peterka M; Ksandrova M; Benesova S; Neuzil J; Andera L
Biochim Biophys Acta Mol Cell Res; 2018 Mar; 1865(3):522-531. PubMed ID: 29278689
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy of pancreatic cancer with green fluorescent protein and tumor necrosis factor-related apoptosis-inducing ligand fusion gene expression driven by a human telomerase reverse transcriptase promoter.
Katz MH; Spivack DE; Takimoto S; Fang B; Burton DW; Moossa AR; Hoffman RM; Bouvet M
Ann Surg Oncol; 2003 Aug; 10(7):762-72. PubMed ID: 12900367
[TBL] [Abstract][Full Text] [Related]
6. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
7. The long non-coding RNA HOTAIR enhances pancreatic cancer resistance to TNF-related apoptosis-inducing ligand.
Yang SZ; Xu F; Zhou T; Zhao X; McDonald JM; Chen Y
J Biol Chem; 2017 Jun; 292(25):10390-10397. PubMed ID: 28476883
[TBL] [Abstract][Full Text] [Related]
8. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells.
Wang P; Zhang J; Bellail A; Jiang W; Hugh J; Kneteman NM; Hao C
Cell Signal; 2007 Nov; 19(11):2237-46. PubMed ID: 17693058
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in established and primary glioma cell lines.
Jaganathan J; Petit JH; Lazio BE; Singh SK; Chin LS
Neurosurg Focus; 2002 Sep; 13(3):ecp1. PubMed ID: 15844877
[TBL] [Abstract][Full Text] [Related]
11. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
[TBL] [Abstract][Full Text] [Related]
12. TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells.
Uno K; Inukai T; Kayagaki N; Goi K; Sato H; Nemoto A; Takahashi K; Kagami K; Yamaguchi N; Yagita H; Okumura K; Koyama-Okazaki T; Suzuki T; Sugita K; Nakazawa S
Blood; 2003 May; 101(9):3658-67. PubMed ID: 12506034
[TBL] [Abstract][Full Text] [Related]
13. Metformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulation in Pancreatic Cancer Cells.
Tanaka R; Tomosugi M; Horinaka M; Sowa Y; Sakai T
PLoS One; 2015; 10(5):e0125779. PubMed ID: 25955843
[TBL] [Abstract][Full Text] [Related]
14. Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer.
Ozawa F; Friess H; Kleeff J; Xu ZW; Zimmermann A; Sheikh MS; Büchler MW
Cancer Lett; 2001 Feb; 163(1):71-81. PubMed ID: 11163110
[TBL] [Abstract][Full Text] [Related]
15. The alkyllysophospholipid edelfosine enhances TRAIL-mediated apoptosis in gastric cancer cells through death receptor 5 and the mitochondrial pathway.
Lim SC; Parajuli KR; Han SI
Tumour Biol; 2016 May; 37(5):6205-16. PubMed ID: 26615420
[TBL] [Abstract][Full Text] [Related]
16. HIF-2α dictates the susceptibility of pancreatic cancer cells to TRAIL by regulating survivin expression.
Harashima N; Takenaga K; Akimoto M; Harada M
Oncotarget; 2017 Jun; 8(26):42887-42900. PubMed ID: 28476028
[TBL] [Abstract][Full Text] [Related]
17. The HSP70 and autophagy inhibitor pifithrin-μ enhances the antitumor effects of TRAIL on human pancreatic cancer.
Monma H; Harashima N; Inao T; Okano S; Tajima Y; Harada M
Mol Cancer Ther; 2013 Apr; 12(4):341-51. PubMed ID: 23371857
[TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor-related apoptosis-inducing ligand inhibits the growth and aggressiveness of colon carcinoma via the exogenous apoptosis signaling pathway.
Gong H; Cheng W; Wang Y
Exp Ther Med; 2019 Jan; 17(1):41-50. PubMed ID: 30651763
[TBL] [Abstract][Full Text] [Related]
19. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells.
Khanbolooki S; Nawrocki ST; Arumugam T; Andtbacka R; Pino MS; Kurzrock R; Logsdon CD; Abbruzzese JL; McConkey DJ
Mol Cancer Ther; 2006 Sep; 5(9):2251-60. PubMed ID: 16985059
[TBL] [Abstract][Full Text] [Related]
20. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP
Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
